We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
+$302M
Cap. Flow
+$392M
Cap. Flow %
37.44%
Top 10 Hldgs %
55.13%
Holding
117
New
33
Increased
29
Reduced
19
Closed
19

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$17.7M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$17.6M
3
NUVL
Nuvalent
NUVL
+$13.7M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$11.3M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$8.63M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$12.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$11.5M
3
SYRE icon
Spyre Therapeutics
SYRE
+$7.13M
4
ARWR icon
Arrowhead Research
ARWR
+$5.64M
5
SLNO
Soleno Therapeutics
SLNO
+$3.9M

Sector Composition

Rank Sector Weight
1 Healthcare 55.37%
2 Financials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
101
Celldex Therapeutics
CLDX
$2.77B
– –
-9,992
Closed -$252K
CMPS
102
Compass Pathways
CMPS
$1.52B
– –
-850,512
Closed -$3.21M
KZR
103
DELISTED
Kezar Life Sciences
KZR
– –
-142,316
Closed -$956K
MESO
104
PUT
Mesoblast
MESO
$1.99B
– –
-838,600
Closed -$16.6M
NMRA icon
105
CALL
Neumora Therapeutics
NMRA
$276M
– –
-475,000
Closed -$5.04M
RAPT
106
DELISTED
RAPT Therapeutics
RAPT
– –
-125,000
Closed -$1.58M
FLNA
107
PUT
Filana Therapeutics
FLNA
$43M
– –
-1,739,400
Closed -$4.1M
SLNO
108
CALL
DELISTED
Soleno Therapeutics
SLNO
– –
-200
Closed -$8.99K
SVRA icon
109
Savara
SVRA
$1.13B
– –
-410,586
Closed -$1.26M
BBOT
110
BridgeBio Oncology
BBOT
$707M
– –
-250,000
Closed -$2.63M
TECX
111
Tectonic Therapeutic
TECX
$573M
– –
-58,331
Closed -$2.69M
SYRS
112
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-150,000
Closed -$34.5K
SYRS
113
PUT
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-1,541,200
Closed -$354K
NARI
114
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-25,000
Closed -$1.28M
1 2 3 4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return

Affinity Asset Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Affinity Asset Advisors held 117 positions worth $1.05B, up 40% from $746M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Affinity Asset Advisors deployed $392M of net new capital in Q1 2025, opening 33 new positions and adding to 29 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 30,000 shares worth $16.8M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 78% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Crinetics Pharmaceuticals, an estimated $11.5M trimmed.

  • Affinity Asset Advisors's largest Q1 2025 buy was State Street SPDR S&P 500 ETF Trust: 30,000 shares worth $16.8M.
  • Affinity Asset Advisors added most to Travere Therapeutics in Q1 2025, an estimated $17.7M increase.
  • Affinity Asset Advisors's biggest Q1 2025 reduction was Crinetics Pharmaceuticals, cutting an estimated $11.5M.
  • Affinity Asset Advisors fully exited Arvinas in Q1 2025, selling an estimated $12.1M.
  • Affinity Asset Advisors's ten largest holdings make up 55% of its $1.05B portfolio in Q1 2025.
  • Affinity Asset Advisors opened 33 new positions and closed 19 in Q1 2025.
  • Affinity Asset Advisors's portfolio value rose 40% quarter-over-quarter to $1.05B.

Based on Affinity Asset Advisors's 13F filing for Q1 2025, filed 14 May 2025.